Oncocyte Corp
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
IMDX$2.50+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements and Supplementary Data
Item 8. Financial Statements and Supplementary Data
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2023
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (Marcum LLP) | 62 |
| Report of Independent Registered Public Accounting Firm (WithumSmith+Brown, PC) | 63 |
| Consolidated Balance Sheets | 65 |
| Consolidated Statements of Operations | 66 |
| Consolidated Statements of Comprehensive Loss | 67 |
| Consolidated Statements of Series A Redeemable Convertible Preferred Stock and Shareholders’ Equity | 68 |
| Consolidated Statements of Cash Flows | 69 |
| Notes to Consolidated Financial Statements | 70 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.